TCON (TRACON Pharmaceuticals, Inc.) Projected Sales Volume

Corporate company logo of TRACON Pharmaceuticals, Inc. (TCON)

TRACON Pharmaceuticals (TCON) seeks stable revenue through the optimization of clinical trials for oncology drugs. A chart of the company's projected sales volumes is available in the GURU.Markets system, where 0.01 shows the current value of the metric. However, reducing trial timelines via its own CRO faces a critical barrier: asset liquidation and a lack of grants following the failure of final studies.

Company Future Revenue: TRACON Pharmaceuticals (TCON) for 07/04/2022 - 08/04/2024

Analytical breakdowns for TRACON Pharmaceuticals

- business market valuation indicators:
Fundamental company analysis:TRACON Pharmaceuticals, Inc
Brand item of TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals revenues depend on royalties and upfront payments for the development of targeted cancer therapies. This indicator determines the probable revenue range by comparing current inflows with the mathematical expectation. Growth in this metric signals high business adaptability, although extreme values increase the risk of a correction. By analyzing the company's target sales level, an investor assesses profit potential. Exceeding the upper boundary of the distribution on this chart confirms aggressive growth in commercial potential.

Competitors of TRACON Pharmaceuticals (TCON)

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|Company Projected Revenue metagenomi.co|Projected Sales Volume Precision BioSciences Inc.|Projected Sales Volume GBIO|Boundless Bio, Inc. - Company Revenue Forecast|Projected Sales Volume XCUR (Exicure, Inc.)|Company Future Sales Imunon, Inc. (IMNN)|PHIO - Company Projected Revenue|Company Future Revenue MBIO (mustangbio.com)|RNAZ: Projected Sales Volume|Company Revenue Forecast BNGO|APDN (Applied DNA Corp) - Projected Sales Volume|BLUE: Company Future Revenue|Company Projected Revenue ImmunoPrecise (IPA)|OMGA - Company Expected Sales Volume|Company Projected Revenue Singular Genomics OMIC|Company Future Revenue RGLS|Syros Pharmaceuticals, Inc. - Projected Sales Volume|Company Future Sales Telesis Bio Inc. TBIO|UBX: Projected Sales Volume